MannKind Corporation NNFN.F Stock
MannKind Corporation Price Chart
MannKind Corporation NNFN.F Financial and Trading Overview
MannKind Corporation stock price | 3.96 EUR |
Previous Close | 3.76 EUR |
Open | 3.77 EUR |
Bid | 3.81 EUR x 0 |
Ask | 3.85 EUR x 0 |
Day's Range | 3.77 - 3.77 EUR |
52 Week Range | 3.01 - 5.24 EUR |
Volume | 1K EUR |
Avg. Volume | 40 EUR |
Market Cap | 996.17M EUR |
Beta (5Y Monthly) | 1.562323 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.04 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.17 EUR |
NNFN.F Valuation Measures
Enterprise Value | 1.24B EUR |
Trailing P/E | N/A |
Forward P/E | -22.170588 |
PEG Ratio (5 yr expected) | -0.45 |
Price/Sales (ttm) | 7.7580867 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 9.669 |
Enterprise Value/EBITDA | -27.852 |
Trading Information
MannKind Corporation Stock Price History
Beta (5Y Monthly) | 1.562323 |
52-Week Change | 22.59% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.24 EUR |
52 Week Low | 3.01 EUR |
50-Day Moving Average | 3.8 EUR |
200-Day Moving Average | 4.04 EUR |
NNFN.F Share Statistics
Avg. Volume (3 month) | 40 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 264.31M |
Float | 258.52M |
Short Ratio | N/A |
% Held by Insiders | 2.35% |
% Held by Institutions | 52.68% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -55.44% |
Operating Margin (ttm) | -39.50% |
Gross Margin | 51.16% |
EBITDA Margin | -34.71% |
Management Effectiveness
Return on Assets (ttm) | -10.45% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 128.4M EUR |
Revenue Per Share (ttm) | 0.49 EUR |
Quarterly Revenue Growth (yoy) | 238.79% |
Gross Profit (ttm) | 42.27M EUR |
EBITDA | -44574000 EUR |
Net Income Avi to Common (ttm) | -71197000 EUR |
Diluted EPS (ttm) | -0.26 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 166.14M EUR |
Total Cash Per Share (mrq) | 0.63 EUR |
Total Debt (mrq) | 382.91M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.728 |
Book Value Per Share (mrq) | -0.966 |
Cash Flow Statement
Operating Cash Flow (ttm) | -61275000 EUR |
Levered Free Cash Flow (ttm) | -53032248 EUR |
Profile of MannKind Corporation
Country | Germany |
State | CT |
City | Danbury |
Address | 1 Casper Street |
ZIP | 06810 |
Phone | 818 661 5000 |
Website | https://www.mannkindcorp.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 391 |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Q&A For MannKind Corporation Stock
What is a current NNFN.F stock price?
MannKind Corporation NNFN.F stock price today per share is 3.96 EUR.
How to purchase MannKind Corporation stock?
You can buy NNFN.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for MannKind Corporation?
The stock symbol or ticker of MannKind Corporation is NNFN.F.
Which industry does the MannKind Corporation company belong to?
The MannKind Corporation industry is Biotechnology.
How many shares does MannKind Corporation have in circulation?
The max supply of MannKind Corporation shares is 270.76M.
What is MannKind Corporation Price to Earnings Ratio (PE Ratio)?
MannKind Corporation PE Ratio is now.
What was MannKind Corporation earnings per share over the trailing 12 months (TTM)?
MannKind Corporation EPS is -0.04 EUR over the trailing 12 months.
Which sector does the MannKind Corporation company belong to?
The MannKind Corporation sector is Healthcare.